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Abstract
TDP-43-mediated proteinopathy is a key factor in the pathology of amyotrophic lateral scle-
rosis (ALS). A potential underlying mechanism is dysregulation of the cytoskeleton. Here we
investigate the effects of expressing TDP-43 wild-type and M337V and Q331K mutant iso-
forms on cytoskeletal integrity and function, using rat cortical neurons in vitro. We find that
TDP-43 protein becomes mislocalised in axons over 24–72 hours in culture, with protein
aggregation occurring at later timepoints (144 hours). Quantitation of cell viability showed
toxicity of both wild-type and mutant constructs which increased over time, especially of the
Q331K mutant isoform. Analysis of the effects of TDP-43 on axonal integrity showed that
TDP-43-transfected neurons had shorter axons than control cells, and that growth cone
sizes were smaller. Axonal transport dynamics were also impaired by transfection with
TDP-43 constructs. Taken together these data show that TDP-43 mislocalisation into axons
precedes cell death in cortical neurons, and that cytoskeletal structure and function is
impaired by expression of either TDP-43 wild-type or mutant constructs in vitro. These data
suggest that dysregulation of cytoskeletal and neuronal integrity is an important mechanism
for TDP-43-mediated proteinopathy.
Introduction
It is well established that mutations of the TAR DNA-binding protein 43 (TDP-43), a highly
conserved nuclear protein, are causal of Amyotrophic Lateral Sclerosis (ALS), and in the most
common variant of Frontotemporal Lobe Dementia, FTLD-U [1–4]. Several groups have iden-
tified mutations in TDP-43 in sporadic and familial cases of ALS and have provided evidence
of a direct link between TDP-43 dysfunction and neurodegeneration[3–5]. Previous studies in
transgenic animal models have shown that over-expression of wild-type and mutant isoforms
of TDP-43 is toxic and can cause neurodegeneration.
TDP-43 is predominantly a nuclear protein, although it is actively shuttled between the
nucleus and the cytoplasm [6] However, under pathological conditions, TDP-43 is depleted
from the nucleus and accumulates in the cytoplasm in both neurons and glia [7, 8]. Thus
TDP-43 proteinopathies could be caused by a loss of function due to nuclear depletion, by a
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gain of function due to cytoplasmic aggregation, or by a combination of both [1, 9–11]. Patho-
logical TDP-43 is abnormally ubiquitinated, hyperphosphorylated and N-terminally cleaved to
generate C-terminal fragments (20–25 kDa) [12]. The fundamental question as to whether
TDP-43 mediates neurodegeneration via a gain of function or a loss of function remains
unanswered.
TDP-43 is an RNA binding protein which plays an important role in mRNA transport, sta-
bility, and translation [13, 14]. TDP-43 directly interacts with the 3’UTR of neurofilament
light chain (68 kDa) mRNA to stabilise it [15], and associates with futsch (MAP1B) mRNA in a
complex in vivo to regulates its localization and translation in Drosophila motor neurons [16].
Hence, a plausible hypothesis is that TDP-43 brings about neuronal death by dysregulation of
cytoskeletal components [17]. TDP-43 has been shown to play a role in the regulation of axon
growth and in axonal transport [6, 18].
Most studies have used transgenic animals and cell lines to investigate TDP-43 pathome-
chanisms with fewer studies on primary neurons [6, 19, 20]. We have previously shown that in
chick spinal motor neurons and in vitro and in vivo, TDP-43 mis-localises in axons, coinciding
with a reduction in axonal length and an increase in cellular toxicity [21]. In the present study,
primary cortical neurons are a relevant cell type due to the involvement of TDP-43 in
FTLD-U, which affects cortical neurons.
Here we compare the effects of transfecting into rat cortical neurons wild-type TDP-43,
and two mutant isoforms containing the M337V familial mutation or the Q331K sporadic
mutation. Both are missense mutations in the highly conserved glycine-rich C-terminus of
TDP-43 which mediates protein-protein interactions [4]. These two mutants were shown to
provoke age-dependent, progressive motor neuron degeneration when expressed in mice at
levels similar to endogenous TDP-43 [22]. We have previously shown that both TDP-43
mutant isoforms also cause apoptosis in the chick spinal cord, suggesting a toxic gain of
function or dominant-negative effect [4]. The effects of TDP-43 overexpression on toxicity,
the localisation of TDP-43 protein, axonal growth, cytoskeletal integrity and axonal trans-
port were analysed using toxicity assays, immunohistochemistry and live imaging.
Materials and methods
Plasmids
The GFP-tagged WT-TDP-43, M337V-TDP-43 and Q331K-TDP-43 constructs and GFP con-
trol plasmids were as described previously [21]. The EB3-RFP construct was a gift from Maddy
Parsons’s lab (Randall Division of Cell & Molecular Biophysics).
Primary rat cortical neuron cultures and transfection
Sprague-Dawley rats pregnant with E18 embryos were obtained from Charles River UK, Ltd.,
located in Manston Road. Margate CT9 4LT. The animals were bred for research purposes.
E18 rat cortices were dissected in ice-cold Hanks Buffered Salt Solution (HBSS; Invitrogen),
equilibrated for 2 minutes, and incubated with trypsin diluted 1:4 in HBSS for 15 mins at 37˚C
with intermittent shaking for 15 mins. Trypsin inhibitor solution was then added and the cor-
tices were dissociated by trituration and centrifuged for 5 mins at 1200 rpm. The supernatant
was removed, the pellet was re-suspended in 5 ml of pre-warmed HBSS, passed through a 70
µm filter and re-centrifuged as above. The pellet was resuspended in 2ml of pre-warmed HBSS
and the number of cells was counted using a haemocytometer. For non-transfected cells,
80,000 cells from the cell suspension was centrifuged at 1800 rpm for 5 mins and the pellet was
re-suspended in 400 µl of culture medium per well.
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For transfection, the required number of cells (4–5 x 106 cells per plasmid construct) to be
transfected was centrifuged at 1800 rpm for 5 mins. The neurons were transfected using an
Amaxa machine with rat neuron nucleofector solution (Lonza). The cell pellet was resus-
pended in 100 µl of nucleofector solution with 4 µg of DNA, transferred into the Amaxa
cuvette and transfected using the O-003 program. 200 µl of pre-equilibrated culture medium
was added and cells were plated at a density of 100,000 cells in 400 µl of culture medium per
well. Transfection efficiency was ~70%.
Neurons were cultured on 13 mm round coverslips that had previously been coated with
poly-lysine and laminin (Sigma-Aldrich) in multiwell plates (Nunc). Confocal dishes (Ibidi)
were used for live imaging. The culture medium was Neurobasal with 2% B-27, 1% glutamax
and 1% penicillin-streptomycin (all from Invitrogen) with 2% horse serum (Sigma-Aldrich).
Cultures were incubated at 37˚C with 5% CO2 for 24–120 h. For cultures that were maintained
for< 48 h, the medium was replaced every two days.
Immunocytochemistry
Primary antibodies used were chick anti-GFP (1:1000; Abcam), rabbit anti-TDP43 (1:1000;
Cell Signalling), rabbit anti-neurofilament-H (1:1000; Millipore), rat anti-tyrosinated tubulin
(1:1000; Abcam) and rabbit anti-Glu-tubulin (1:1000; Abcam). Secondary antibodies were
anti-rabbit Cy-3-conjugated, anti-chick Alexafluor488, anti-rabbit Alexafluor 568 and anti-rat
Alexafluor 568 (all at 1:1000; Life Technologies).
Coverslips were fixed by adding 400 µl of 4% paraformaldehyde (PFA)/15% sucrose
(Sigma-Aldrich) to each well for 15 mins at room temp, then washed twice with PBS-T (1 X
phosphate-buffered saline (PBS) + 0.1% Triton X-100) and rocking. Non-specific binding was
blocked using 0.5% bovine serum albumin (BSA; Sigma) in PBS for 1 h at room temp. Cover-
slips were incubated in primary antibodies diluted as above in 0.1% PBS-T with 0.5% FBS,
overnight on a rocker at 4˚C, then washed 3 X 10 mins with PBS-T on a rocker plate at room
temperature, followed by incubation in secondary antibodies as above in PBS-T for 1–2 h at
room temperature with rocking. After further washes, the coverslips were mounted on slides
using Fluorsave (Calbiochem) with Hoechst reagent (Thermo-Fisher Scientific).
TUNEL toxicity assay
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) was used to detect
fragmented DNA associated with cell apoptosis, using the DeadEnd colorimetric TUNEL sys-
tem (Promega) according to the manufacturer’s instructions. Before starting the assay, cells
were permeabilised for 5 mins with 100 µl of 20 µg/ml of Proteinase K in PBS-T. Coverslips
were washed twice with PBS-T with 2 mg/ml of glycine, then fixed for 5 mins with 4% PFA,
and washed twice with PBS-T. After the diaminobenzidine staining step of the assay, coverslips
were washed several times with water, fixed with 4% PFA for 10 mins and immunostained
with the respective primary and secondary antibodies as above.
The TUNEL-positive cells appeared as black dots and were manually counted from five dif-
ferent 0.24 mm2 fields from a 13 mm coverslip. A comparison with the Hoechst nuclear stain-
ing (Invitrogen) using blue epifluorescence gave the total cell numbers. Three coverslips from
three experiments per condition was used to average the number of TUNEL-positive cells.
Cell viability assay
Cortical neuron cultures were plated on white opaque-walled 96 well plates. Cell viability was
monitored using a continuous read format with the Promega RealTime-Glo™ MT Cell Viabil-
ity Assay. The MT Cell Viability Substrate and NanoLuc1 Enzyme were added to the culture
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medium at the dosage specified by the protocol, plates were re-incubated for 4 h and the first
luminescence reading was taken 24 h after transfection and every 24 h thereafter using a lumi-
nescent plate reader. The average relative light unit (RLU) from three different experiments, as
measured by the luminometer, was plotted for the different constructs against the different
time-points.
Live imaging of cortical neurons
For live imaging, neurons were plated on confocal dishes at a density of 160,000 cells per well
in 1 ml of medium. For EB3 imaging, rat cortical neurons were co-transfected with equal
quantities of the GFP control plasmid or TDP-43 wild-type and mutant plasmids together
with an RFP-tagged EB3 plasmid. Neurons were imaged in a Nikon Live imaging chamber
microscope maintained at 37˚C with 5% CO2. Transfected neurons that expressed GFP were
imaged at 60X with the DIC channel for 30 mins with 2–5 sec intervals using Nikon Elements
software.
Axon length and growth cone analysis
For axon length measurements, the length of 100 neurons per transfection per experiment
(n = 3) were measured using neuron J, selecting healthy neurons with an uninterrupted axon
that was at least 3 times the length of the cell body.
The growth cones of neurons labelled with anti-GFP and anti-tubulin antibodies were
imaged using a Zeiss AxioScop at 63X, and images were processed using Volocity or ImageJ
software. ImageJ was used to quantitate growth cone area, by thresholding the GFP fluores-
cence, drawing an outline and measuring the area in pixels. A total of ~70 neurons per con-
struct were analysed from 3 independent experiments. The graphs were drawn based on the
average area and Standard error of mean.
Kymographs
To quantitate EB3 ‘comet’ velocities along axons, we used kymographs, made using ImageJ
and analysed using KymoquantTM software, which calculates the velocity of individual EB3
traces based on the angle and tangent of the kymograph patterns. A total of 20 movies from 3
independent experiments were analysed. The graphs were drawn based on the average velocity
in pixels/frame and standard error of mean. Kymographs were drawn for 10 neurons per con-
struct per experiment (n = 3) using Image J.
Statistics
Statistics used a one-way Anova coupled with Dunn’s multiple comparison test.
Ethics
The research was approved by the Home Office UK and the ethics committee of Kings College
London—College Research Ethics Committee (CREC). The Project was reviewed by the Bio-
medical Sciences, Medicine, Dentistry and Natural & Mathematical Sciences Research Ethics
Sub-Committee (BDM RESC). The rats used in the experiments were humanely killed by cer-
vical dislocation, under the “Schedule 1 to the animals (Scientific Procedure) Act 1986”.
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Results
TDP-43 is mislocalised and aggregated in cortical neurons
TDP-43 protein aggregation and mislocalisation is a hallmark of ALS. We have previously
shown that TDP-43 shows enhanced cytoplasmic mislocalisation over time in chick spinal
motor neurons and in the spinal cord in vivo [21]. Given that TDP-43 pathology also occurs in
FTLD-U, which affects the cortex, we determined whether cortical neurons in vitro have the
same vulnerability as spinal motor neurons to TDP-43 pathogenicity.
In order to evaluate TDP-43 mis-localisation and aggregation, cortical neurons were trans-
fected with a control (EGFP) construct, with a GFP-tagged TDP-43 wild-type (WT) construct,
or with M337V or Q331K mutant constructs (here referred to as M and Q) and fixed at time
points from 24 hours to 144 hours. Neurons were immunostained with anti-GFP antibodies to
observe the distribution patterns of GFP control or TDP-43 isoforms. At all four time points,
the GFP control protein was distributed through the entire neuron including axons and den-
drites (Fig 1A–1D). At 24 and 48 hours, TDP-43 wild-type and mutant isoforms were strongly
localised within the cell body, with weaker fluorescence along axons (Fig 1E, 1F, 1I, 1J, 1M and
1N). At 24 hours and t 48 h a lesser extent at 48 hours, TDP-43 WT axonal localisation as
reflected by GFP fluorescence appeared slightly less than for the mutants (Fig 1E', 1I', 1M', 1F',
1J', 1N', 1H', 1L' and 1P'). By 72 hours, this differential was lost and fluorescence in the cell
body and axons was equalised (Fig 1G, 1K, 1O, 1G', 1K' and 1O'). Cultures fixed at 96–144
hours showed an identical pattern (data not shown; Fig 1H, 1L, 1P, 1H', 1L' and 1P').
As a control for the tagged TDP-43 distribution, neurons were immunostained for tyrosi-
nated tubulin, which is distributed throughout the neuron. Tubulin staining was seen through-
out neurons transfected with all constructs at 24–144 hour timepoints, showing an even
distribution relative to GFP, and validating the changes in TDP-43 localisation that were
observed (Fig 2A–2R, 2S–2U, 2Y–2A' and 2E'–2G').
Transfected neurons were next double-labelled with antibodies to GFP (green) and TDP-43
(red); the latter detected both the endogenous (rat) protein and the transfected (human) pro-
tein. At 24, 72 and 144 hours, TDP-43 protein was detected only in the nuclei of neurons trans-
fected with the GFP control, as expected (Fig 3A–3F). At 24 hours for WT and mutant TDP-
43 tranfections, the protein was present at a low level in axons (data not shown), whereas at 72
and 144 hours, TDP-43 protein distribution was increased in the axons (Fig 3G–3Z). However,
both the GFP-tagged TDP-43 and the immunostained TDP-43 signal appeared grainy, sug-
gesting that TDP-43 protein had aggregated in axons. At 144 hours, this granular appearance
was similar for the wild-type and mutant-transfected neurons (Fig 3J–3Z, 3M, 3T and 3A’).
For the majority of neurons, it does not appear that this phenomenon is due to axonal frag-
mentation as opposed to protein aggregation, as axons appeared intact based on anti-tubulin
immunostaining (data not shown; Fig 2S–2U, 2Y–2A’ and 2E’–2G’).
We observed that in cultures from 72 hours onwards (data not shown) and particularly at
144 hours, a minority of neurons in the WT and mutant TDP-43 transfected cultures showed
evidence of axonal disintegration and cell death. At 144 hours, dying or dead cells appeared as
a series of spots, which were GFP-positive (reflecting TDP-43 localisation) and tubulin-posi-
tive (Fig 2V–2X, 2B’–2D’ and 2H’–2J’).
We have therefore shown that TDP-43 wild-type and mutant proteins were re re-distrib-
uted to axons over 0–72 hours, whereas at 144 hours, there is a suggestive appearance of aggre-
gate formation, with evidence of neuronal fragmentation. However, fractionation assays have
to be done to ascertain the nature of these aggregates. These data suggest that the mislocalisa-
tion of TDP-43 protein in cortical axons precedes neuronal disintegration.
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Over-expression of wild-type and mutant TDP-43 isoforms causes
neurotoxicity in cortical neurons
We have previously shown that over-expression of the wild-type and mutant isoforms of TDP-
43 causes neurotoxicity in vivo in chick embryo spinal cord [21]. In order to further investigate
the cell death mentioned above, we quantitated neuronal cell death in cortical neurons using a
Fig 1. TDP-43 is mislocalised in cortical neurons. Rat cortical neurons were transfected with GFP control (A—D),
and GFP-tagged TDP-43 wild-type and mutant isoforms (E—P) and analysed at 24–144 hours (H). Immunostained
with anti-GFP antibodies. Scale bar = 10 µm. Insets (E’–P’)—higher power views of the corresponding panels above,
converted to black and white pixels. Scale bar = 10 µm.
https://doi.org/10.1371/journal.pone.0196528.g001
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TUNEL and a fluorometric cell viability assay, over 24–168 hours in culture. For the TUNEL
assay, dead cells were counted manually at 24–72 hours (Fig 4A–4D). EGFP-expressing con-
trol neurons had few apoptotic cells at all three time points whereas the number of apoptotic
Fig 2. Cytoskeletal integrity is compromised over time in cortical neurons. Rat cortical neurons were transfected with GFP control, or GFP-
tagged TDP-43 wild-type and mutant isoforms as labelled and analysed at 24, 72 H and 144 H. Immunostaining with anti-GFP (green) and
anti-tyrosinated tubulin (red) antibodies. Cellular fragmentation was observed at 144 H (bottom right panel). Scale bar = 10 µm.
https://doi.org/10.1371/journal.pone.0196528.g002
TDP-43 is neurotoxic in ALS
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cells was significantly higher for neurons expressing TDP-43 isoforms (Fig 4E). At 24–72 hour
time points, the neurons over-expressing the wild-type and mutant isoforms of TDP-43
showed a significant increase in the number of apoptotic cells compared to the neurons
expressing EGFP ( p< 0.01,  p < 0.001,  p< 0.0001; Fig 4E). There was no significant
difference in toxicity between the TDP-43 wild-type and mutant constructs at each timepoint
(p> 0.05). Overall, the numbers of apoptotic cells in TDP-43-transfected cultures were found
to increase between 24 and 72 hours. In particular, the TDP-43 transfected cells showed a sig-
nificant increase in cell death between 24 and 48 hours, and between 48 and 72 hours (
p< 0.01,  p<0.001,  p<0.0001: Fig 4E).
We also determined cell viability using a bioluminescent assay which is non-lytic and mea-
sures the metabolic activity of cells. We found that the GFP-transfected control cells showed
greater viability than the TDP-43 transfected neurons at all timepoints, with an increase in cell
numbers from 24–72 hours which likely reflects cell division in vitro (Fig 4F). There was a
slight decrease in the viability of GFP-transfected cells between 72 and 168 hours in vitro, but
overall, they showed a ~1.5 – 2x enhancement of viability relative to cells transfected with
TDP-43 isoforms. All three TDP-43-transfected cell populations showed a decline in neuronal
numbers between 72 and 168 hours (WT and M mutant) or 48 hours and 168 hours (Q
mutant). These data suggest that the viability of neurons transfected with WT and mutant
Fig 3. TDP-43 mislocalisation visualised with anti-TDP-43 antibodies. Rat cortical neurons were transfected with GFP control, and GFP-tagged TDP-43
wild-type and mutant isoforms as labelled and analysed at 72 H and 144 H. Immunostaining with anti-GFP (green) and anti-TDP-43 antibodies (red). Scale
bar– 10 µm. Insets—higher power views of corresponding panels to the left, stained with anti-TDP-43 antibodies. Scale bar = 10 µm.
https://doi.org/10.1371/journal.pone.0196528.g003
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Fig 4. TDP-43 isoforms mediate toxicity in vitro. Control and TDP-43 transfected neurons (as labelled) were stained
using a TUNEL kit and imaged to show TUNEL-positive cells (black dots) and Hoechst staining (white dots) after 72H
in culture (A—D). Scale bar = 10 µm. (E) Average number of apoptotic cells quantified from five 0.24mm2 fields, at 3
time points as shown (3 experiments). Data is presented as means and standard errors. Significance was compared by
ANOVA with GFP control at the respective timepoint and between constructs at various timepoints (no significance:
TDP-43 is neurotoxic in ALS
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TDP-43 isoforms is significantly lower than for control cells, with the Q mutant showing the
highest toxicity, and with an earlier onset. We conclude that TDP-43 isoforms cause a broadly
similar level of toxicity in primary cortical neurons in vitro, with a slightly increased effect of
the Q mutant construct.
TDP-43 affects axonal growth and growth cone size in vitro
In order to characterize the effects of TDP-43 on cortical axon outgrowth, axon lengths were
measured at 24–72 hours post-transfection after immunostaining with anti-GFP antibodies.
Quantification suggested that control GFP-transfected neurons were longest at all time points
whereas at 24 and 48 hours the TDP-43 transfected neurons (wild-type and mutants) show a
modest reduction in neuronal length compared to the controls, which were significant at the
p< 0.0001 level (Fig 5A). At 72 hours, it was surprising to note that the TDP-43 WT construct
resulted in significantly shorter axons (p< 0.0001) relative to the control, whereas the mutant
constructs produced only a modest reduction relative to the control (p< 0.05). Nevertheless,
all three constructs impaired axon outgrowth in vitro.
We noticed that some transfected cortical neurons had small growth cones, and quantitated
this from 24–72 hours post-transfection by immunostaining with anti-GFP and anti-tubulin
antibodies, and measuring growth cone areas (Fig 5B–5M). GFP-expressing control neurons
have a characteristic ‘palm’ appearance with many filopodial extensions (Fig 5B, 5F and 5J).
Growth cones of neurons transfected with TDP-43 constructs varied in morphology, but there
was a trend for more spiky growth cones with smaller areas than GFP-transfected neurons.
These difference were most pronounced at 72 hours, and both Q and M mutants affected
growth cone morphology more strongly that WT-TDP-43 (Fig 5N and legend).
TDP-43 affects axonal transport
The data obtained so far converge on the possibility that TDP-43 associates either directly or
indirectly with proteins that affect cytoskeletal integrity, axonal outgrowth and growth cone
dynamics. We next tested whether TDP-43 also affects anterograde transport of microtubule
plus tip proteins, by studying the dynamics of EB3, a microtubule-associated protein that
binds to the plus end of microtubules and regulates and promotes microtubule dynamics and
growth [23]. Rat cortical neurons were co-transfected with GFP-tagged TDP-43 constructs
and EB3-RFP and live imaged after 48 and 72 hours in culture. EB3 proteins, termed ‘comets’,
move rapidly in an anterograde manner to the growing tips of axons (Fig 6A and 6A’) and this
movement can be analysed using kymographs.
Kymographs show the tracks of EB3 comets, with the gradient of the tracks representing
the velocity of movement (Fig 6B–6I). The kymographs show that the gradients for GFP con-
trols are shallower than for TDP43-transfected neurons, and that the numbers of EB3 proteins
are in general lower for the TDP M and Q mutants than for the EGFP control or the WT pro-
teins. This suggests there may be fewer microtubules in TDP-Q-transfected cultures in particu-
lar, and that EB3 comets stop short of progressing to the ends of axons (Fig 6H and 6I).
Quantitation of velocities show that there is trend towards the velocities being lower for TDP-
43-transfected neurons than for controls; however these differences were not statistically sig-
nificant (Fig 6J). This raises the possibility that TDP-43 can directly or indirectly impair axonal
transport.
p> 0.05;  P< 0.0001,  P< 0.001,  P< 0.01—compared with GFP control). (F) Semi-quantitative analysis of the
viability of transfected cells assessed by Promega real-time glo viability assay at different time points from 3
experiments.
https://doi.org/10.1371/journal.pone.0196528.g004
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Fig 5. TDP-43 affects axonal growth in vitro. (A) Quantitation of axon lengths of transfected neurons at time-points
as labelled (n = 3 experiments; 100 neurons per experiment). Data is presented as means and standard errors.
Significance were compared by ANOVA between constructs at same time points (no significance—p> 0.05; 
P< 0.01;  P< 0.001;  P< 0.0001). (B)–(M) typical cortical neuron growth cones stained with anti-tyrosinated
tubulin antibodies at timepoints and with constructs as labelled. Scale bar = 10 µm. (N) Quantitation of mean growth
TDP-43 is neurotoxic in ALS
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Discussion
The aim of this study was to shed light on the mechanisms underlying TDP-43-mediated ALS.
We have shown that TDP-43 mis-localises in cortical neurons and that the re-distribution is
enhanced compared to that previously observed in spinal motor neurons [23]. Over-expres-
sion of TDP-43 wild-type and mutant proteins was toxic to cortical neurons and both mis-
localisation and toxicity progressed with time. Rat cortical cells transfected with TDP-43 wild-
type and mutant proteins showed varying phenotypes that reflected defective cytoskeletal
functions; TDP-43 impairs axon outgrowth, microtubule and growth cone dynamics. Overall
our results highlight the importance of cytoskeletal dysregulation as a factor in the pathophysi-
ology of ALS. We have shown that axonal recruitment of TDP-43 begins at 24 hours and pro-
gresses with time, until at 144 hours, dying cells were observed in culture. Our findings are
consistent with our previous studies using motor neurons in vitro and in vivo wherein TDP-
43 showed progressive translocation from the nucleus into axons [21].
TDP-43 wild-type and mutant constructs were neurotoxic and the number of apoptotic
cells increased over time, with the TDP-43 mutant Q331K showing the highest number of apo-
ptotic cells across the different time points. The increased toxicity correlates with the progres-
sive re-distribution of TDP-43. This is in accordance with several studies that show a positive
correlation between TDP-43 toxicity and TDP-43 mislocalisation [24]. Comparatively, cellular
fragmentation and toxicity was more severe in spinal motor neurons at 72 hours [21] whereas
significant protein fragmentation was not observed until 144 hours in cortical neurons, sug-
gesting that the former neuronal type may be more susceptible to TDP-43 aggregation.
A number of lines of evidence in this study showed that disruption of cytoskeletal integrity
occurs in cortical neurons transfected with TDP-43 isoforms. TDP-43 transfected neurons
showed a significant reduction in axon length, consistent with previous findings wherein over-
expression of the TDP-43 WT caused a significant reduction in axon outgrowth in primary
motor neurons when compared to the TDP-43 mutants [6]. TDP-43 transfected neurons also
had smaller growth cones implying a defect in microtubule/actin dynamics. This was also
reflected in the fragmentation of tubulin, implying that aggregation can lead to cell death by
perturbing cytoskeletal integrity. We also report a trend towards decreased axonal transport.
Our results complement our previous findings in vivo wherein TDP-43 caused premature
truncation and de-fasciculation of motor axons in vivo and reduced neurite outgrowth in
chick spinal motor neurons in vitro [21]. The smaller growth cones we observe in this study
could explain the shorter axons in vitro and the premature truncation and debundling/de-fas-
ciculation of axons in vivo in chick spinal cord. It is plausible that growth cone defects could in
turn lead to perturbations of axonal maintenance, which might contribute to
neurodegeneration.
Axonal mRNA transport is considered to be a possible target of RNA-binding protein-
mediated neurodegeneration and is a necessity for local translation [25]. Exome-wide rare var-
iant analysis, identified patient variants of the tubulin alpha 4a (TUB4A) gene in familial ALS,
thereby implicating the role of cytoskeletal defects in ALS [26]. We speculate that impairment
in the mRNA regulation of TDP-43 binding partners may contribute to neurodegeneration via
dysregulation of the axonal cytoskeleton.
The identification of mutations in several cytoskeletal genes in neurodegenerative diseases
have highlighted their importance in the disease pathophysiology. Alzheimer’s disease,
cone area at 3 different time points as labelled (70 neurons per construct per experiment, 3 experiments). Data is
presented as mean and standard error. Significance denoted as for (A).
https://doi.org/10.1371/journal.pone.0196528.g005
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Fig 6. TDP-43 affects anterograde transport in cortical neurons. (A) Example of a cortical neuron co-transfected
with EB3-RFP, live imaged to show EB3 ‘comets’ (arrows) (A’) Higher power view. EB3 moves in an anterograde
manner towards the growing ends of axon. (B)–(I) Example kymographs of neurons expressing GFP, or co-transfected
with GFP and TDP isoforms, at 48 and 72H, as labelled. Distance along the X-axis and time along the Y-axis. Scale
bar = 10 µm, except in A’ (J) Quantification of the velocity of EB3-RFP comets in the axons of transfected neurons.
Graphs represent means and standard error of (n = 3). No significant differences were observed.
https://doi.org/10.1371/journal.pone.0196528.g006
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Parkinsons disease, Tauopathies, ALS, polyglutamine diseases all feature defects in cytoskele-
ton [27]. Cytoskeletal swellings, disruption of axonal transport and accumulation of cytoskele-
tal proteins in the abnormal inclusions are early events in neurodegeneration suggesting that
disruption of the cytoskeleton initiates a cascade of events that eventually leads to atrophic
processes.
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